- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02744027
Imaging of Lymphatic Anomalies
Dynamic Contrast Enhanced MR Lymphangiogram Imaging of Lymphatic Anomalies (LA)
Study Overview
Status
Conditions
Detailed Description
Lymphatic anomalies (LA) are a spectrum of rare diseases classified into lymphatic tumors and malformations. Complicated LA cases in the past have been called lymphangiomatosis because of varied disseminated involvement including soft tissue and viscera such as the spleen, liver and bone. Pleural effusions and pericardial effusions are often associated with these lesions. These are now classified into different phenotypes such as Generalized Lymphatic Anomaly (GLA), Gorham's Stout Disease (GSD) and Kaposiform Lymphangiomatosis (KLA). These complicated phenotypes can cause massive osteolysis causing a morbidity and mortality from infection or paralysis or worsening pulmonary function and effusions (GSD, GLA, KLA).
The major cause of mortality and morbidity in these patients is the deterioration of pulmonary function by chronic chylous effusions and progressive interstitial lung disease. Unfortunately, little is known about biomarkers, risk stratification or the pathophysiology of this progression. The understanding of changes in patients' lymphatic anatomy with LA is hindered by the difficulty of imaging the lymphatic system. Dynamic Contrast Enhanced MR Lymphangiogram (DCMRL) is a technique that has recently been developed, allowing dynamic MR imaging of the lymphatic system by injecting gadolinium contrast agent in the groin lymph nodes.
This technique has been previously used to identify pathological lymphatic perfusion of the lung parenchyma in patients with plastic bronchitis and neonatal chylothorax. Based on these imaging findings, a treatment algorithm has been designed and used to successfully treat the majority of those patients with these conditions.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects diagnosed with Lymphatic Anomalies (GLA, KL, Gorham disease) with radiological and or pathological confirmation of lung involvement will be considered for the study.
- Girls > 11 y.o. with a negative urine pregnancy test and contraception use.
- Registration in the International Lymphangiomatosis and Gorham's Disease Alliance (LGDA) Patient Registry or referral by a physician.
Exclusion Criteria:
- Subjects with contraindications to contrast enhanced MRI: allergy to gadolinium imaging agents, impaired renal function (GFR<30) and presence of paramagnetic objects.
- Claustrophobia or contraindications to sedation/anesthesia
- Uncorrectable coagulopathy (bleeding disorders).
- Pregnant or lactating females.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Dynamic Contrast Enhanced Magnetic Contrast Imaging
Dynamic Contrast Enhanced Magnetic Resonance (MR) Lymphangiogram and heavy T2 Magnetic Resonance imaging data will be evaluated for abnormal lymphatic perfusion of the lung parenchyma.
Abdominal and thoracic lymphatic malformations will be characterized by location, number, size, relationship to other organs and perfusion patterns in order to create a basis of imaging classification of lymphatic abnormalities (LA).
Subjects will undergo both Dynamic Contrast Enhanced Magnetic Resonance Lymphangiogram (DCMRL) and Heavy Weighted T2 Imaging.
|
Following completion of the T2 lymphatic mapping, contrast agent administered will be calculated based on weight.
Investigators will use dosage of 0.1cc/kg of contrast which will be injected by hand simultaneously into each lymphatic node (LN) at a rate of 0.5-1 cc per min.
One minute after the injection, scanning will be initiated using high spatial and temporal resolution magnetic resonance angiography (syngo time-resolved angiography with stochastic trajectories [TWIST]) sequence.
The sequence parameters will be adjusted with a time delay such that a complete volume will be acquired approximately every 20-60 seconds.
This will be followed by additional scans with a high-resolution navigator gated 3-dimensional flash inversion recovery (IR) sequence.
In all subjects the scan area covered the neck, chest, and abdomen as caudal as feasible.
Magnetic Resonance imaging (MRI) will be performed and T2W MRI lymphatic mapping will be performed using a respiratory navigated and cardiac gated 3 dimensional turbo spin echo sequence with pre-set parameters.
Scan time varies from 2-5 min depending upon the size of the subject.
The procedure will be performed under sedation and anesthesia if participants are aged 16 or under. The procedure will be performed with local anesthesia for participants aged over 16 years old. Using ultrasound guidance two inguinal lymph nodes (one each side) will be directly accessed with 25-gauge spinal needles attached to a short connector tubing. A shallow angle for puncture will be used to create a long subcutaneous tract to assist in stabilizing the needle. A small amount of an oil-based contrast or water soluble contrast will be injected under fluoroscopy guidance to confirm the correct position of the needles inside the lymph nodes. After stabilizing the needle, the subjects will be transferred into the MRI suite. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Describe lymphatic anatomy of participants with lymphatic anomalies (LA)
Time Frame: 2 Days
|
The primary endpoint will be the description of lymphatic anatomy assessing if participants have a single or branched Thoracic Duct.
|
2 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of a classification system for lymphatic flow
Time Frame: 2 days
|
Development of a classification system based on retrograde or anterograde flow of lymphatic fluid.
|
2 days
|
Description of Lymphatic malformations in participants with lymphatic anomalies
Time Frame: 2 days
|
Assessing if lymphatic malformation are present or absent in participants with lymphatic anomalies.
|
2 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yoav Dori, MD, PhD, Children's Hospital of Philadelphia
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-012331
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphatic Diseases
-
Palvella Therapeutics, Inc.RecruitingMicrocystic Lymphatic MalformationUnited States
-
University Hospital, ToursRecruitingLingual Microcystic Lymphatic MalformationsFrance
-
Palvella Therapeutics, Inc.Not yet recruitingMicrocystic Lymphatic MalformationUnited States
-
Nanjing Children's HospitalRecruiting
-
Protara TherapeuticsRecruiting
-
Avalo Therapeutics, Inc.WithdrawnLymphatic MalformationUnited States
-
Medical University of South CarolinaRecruiting
-
University Hospital, ToursUniversity Hospital, AngersRecruitingVascular Malformations | Lymphatic MalformationFrance
-
Venthera, Inc., a BridgeBio companyTerminatedLymphatic Malformation | Venous Malformation | Venolymphatic MalformationUnited States
-
West China HospitalCompleted
Clinical Trials on Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL)
-
Radboud University Medical CenterRecruitingLymphatic Diseases | Noonan Syndrome | Lymphatic Disease | Lymphatic System Disorders CongenitalNetherlands
-
University of CincinnatiActive, not recruiting
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
Yale UniversityTerminatedGlioblastoma MultiformeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institute of Dental and Craniofacial...Recruiting
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingOvarian Carcinoma | Malignant Ovarian NeoplasmUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol Specific | Tumors Metastatic to BrainUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingGliosarcoma | Recurrent GlioblastomaUnited States
-
The Hospital for Sick ChildrenCompletedAsthma | Cystic Fibrosis | Heart DiseaseCanada